-
Product Insights
New![]()
Net Present Value Model: SanBio Co Ltd’s SB-623
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Loma Campana-Sb Field, Argentina
Loma Campana-Sb upstream field is located in Neuquen Province, Argentina. The upstream field is owned by Chevron Corp (50%); YPF SA (50%). It is operated by YPF SA. The project started its operations in 2014. Loma Campana-Sb Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves and capital and operating costs....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SBS-1000 in Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SBS-1000 in PainDrug Details:SBS-1000 is under development for the treatment of acute and chronic Pain. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SB-11285 in Solid Tumor Drug Details: SB-11285 is under development for the treatment of immuno-oncology diseases...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-204 in Acne Vulgaris
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SB-204 in Acne Vulgaris Drug Details:SB-204 is under development for the treatment of acne vulgaris. It...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-11285 in Ovarian CancerDrug Details: SB-11285 is under development for the treatment of immuno-oncology diseases including...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-012 in Ulcerative Colitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-012 in Ulcerative ColitisDrug Details:SB-012 is under development for the treatment of ulcerative colitis. The drug...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-24M in Pyoderma Gangrenosum
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-24M in Pyoderma GangrenosumDrug Details:SB-24M is under development for the treatment of pyoderma, pyoderma gangrenosum, pyoderma vegetans...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-206 in Molluscum Contagiosum
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-206 in Molluscum ContagiosumDrug Details:SB-206 is under development for the treatment of molluscum contagiosum caused by...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-01 in Low Back Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SB-01 in Low Back Pain Drug Details:SB-01Â is under development for the treatment of degenerative disc disease...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-01 in Degenerative Disc Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-01 in Degenerative Disc DiseaseDrug Details:SB-01Â is under development for the treatment of degenerative disc disease (DDD)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Merkel Cell Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-11285 in Merkel Cell CarcinomaDrug Details: SB-11285 is under development for the treatment of immuno-oncology diseases...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-121 in Autism Spectrum Disorder (ASD)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SB-121 in Autism Spectrum Disorder (ASD) Drug Details:SB-121 is under development for the treatment of pervasive...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SB-11285 in Triple-Negative Breast Cancer (TNBC) Drug Details: SB-11285 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SB-11285 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SB-11285 in Non-Small Cell Lung CancerDrug Details: SB-11285 is under development for the treatment of immuno-oncology...
-
Product Insights
SB Danbury – Danbury Office Building – Connecticut
Equip yourself with the essential tools needed to make informed and profitable decisions with our SB Danbury - Danbury Office Building - Connecticut report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Oxford Univ/ SBS – Business School – Oxfordshire
Equip yourself with the essential tools needed to make informed and profitable decisions with our Oxford Univ/ SBS - Business School - Oxfordshire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
DTLA Mgmt – SB Omega Residential Tower – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our DTLA Mgmt - SB Omega Residential Tower - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
SB Texas – Las Colinas Office Headquarters – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our SB Texas - Las Colinas Office Headquarters - Texas report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
FS + SB/ Jacob Sonnichsen – Lübeck Residential Complex – Schleswig-Holstein
Equip yourself with the essential tools needed to make informed and profitable decisions with our FS + SB/ Jacob Sonnichsen - Lübeck Residential Complex - Schleswig-Holstein report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.